Kalaris Therapeutics (KLRS) Latest Stock Analysis Report – Oct 15, 2026, 4:00 PM ET
Updated Oct 15, 2026, 4:00 PM ET
- Closed at $2.19, +2.82% vs the prior close of $2.13.
- Volume 57.00K shares, 0.9x its 50-day average.
- No new SEC filings since the prior session.
- No new insider buys or sales reported since the prior session.
KLRS rises 2.8% to $2.19. Closed at $2.19, +2.82% vs the prior close of $2.13. Day range $2.10–$2.22, opened at $2.20.
KLRS daily analysis — what happened
A plain-English, data-only note written after every US trading day. Newest first; older days stay archived below.
Oct 15, 2026 — KLRS rises 2.8% to $2.19
- Closed at $2.19, +2.82% vs the prior close of $2.13. Day range $2.10–$2.22, opened at $2.20.
- Volume was 57.00K shares, 0.9x its 50-day average of 65.98K.
- Price is -35.6% vs its 50-day average ($3.40) and -62.1% vs its 200-day average ($5.78).
- 52-week range $2.10–$11.88; today's close sits at 1% of that range, 81.6% below the 52-week high.
Oct 14, 2026 — KLRS slides 4.5% to $2.13, a 52-week low, 7 down days in a row
- Closed at $2.13, -4.48% vs the prior close of $2.23. Day range $2.11–$2.23, opened at $2.22.
- Volume was 21.00K shares, 0.3x its 50-day average of 68.23K — lighter than usual.
- Price is -38.1% vs its 50-day average ($3.44) and -63.3% vs its 200-day average ($5.81).
- 52-week range $2.11–$11.88; today's close sits at 0% of that range, 82.1% below the 52-week high.
- That makes 7 straight losses.
Oct 13, 2026 — KLRS dips 1.3% to $2.23, a 52-week low, 6 down days in a row
- Closed at $2.23, -1.33% vs the prior close of $2.26. Day range $2.20–$2.30, opened at $2.27.
- Volume was 73.30K shares, 1.0x its 50-day average of 69.90K.
- Price is -36.0% vs its 50-day average ($3.48) and -61.9% vs its 200-day average ($5.85).
- 52-week range $2.20–$11.88; today's close sits at 0% of that range, 81.2% below the 52-week high.
- That makes 6 straight losses.
Oct 12, 2026 — KLRS slides 4.2% to $2.26, a 52-week low, 5 down days in a row
- Closed at $2.26, -4.24% vs the prior close of $2.36. Day range $2.22–$2.37, opened at $2.37.
- Volume was 122.10K shares, 1.8x its 50-day average of 68.89K.
- Price is -35.8% vs its 50-day average ($3.52) and -61.6% vs its 200-day average ($5.88).
- 52-week range $2.22–$11.88; today's close sits at 0% of that range, 81.0% below the 52-week high.
- That makes 5 straight losses.
Oct 9, 2026 — KLRS slides 5.6% to $2.36, a 52-week low, 4 down days in a row
- Closed at $2.36, -5.60% vs the prior close of $2.50. Day range $2.36–$2.55, opened at $2.46.
- Volume was 104.40K shares, 1.5x its 50-day average of 68.33K.
- Price is -33.4% vs its 50-day average ($3.55) and -60.1% vs its 200-day average ($5.92).
- 52-week range $2.35–$11.88; today's close sits at 0% of that range, 80.1% below the 52-week high.
- That makes 4 straight losses.
Oct 8, 2026 — KLRS dips 2.3% to $2.50, a 52-week low, 3 down days in a row
- Closed at $2.50, -2.34% vs the prior close of $2.56. Day range $2.35–$2.60, opened at $2.60.
- Volume was 110.00K shares, 1.6x its 50-day average of 68.13K.
- Price is -29.9% vs its 50-day average ($3.57) and -58.0% vs its 200-day average ($5.96).
- 52-week range $2.35–$11.88; today's close sits at 2% of that range, 79.0% below the 52-week high.
- That makes 3 straight losses.
Oct 7, 2026 — KLRS slides 3.8% to $2.56, a 52-week low
- Closed at $2.56, -3.76% vs the prior close of $2.66. Day range $2.53–$2.69, opened at $2.59.
- Volume was 74.10K shares, 1.1x its 50-day average of 69.01K.
- Price is -28.6% vs its 50-day average ($3.59) and -57.3% vs its 200-day average ($5.99).
- 52-week range $2.51–$11.88; today's close sits at 1% of that range, 78.5% below the 52-week high.
Oct 6, 2026 — KLRS slides 6.0% to $2.66, a 52-week low
- Closed at $2.66, -6.01% vs the prior close of $2.83. Day range $2.61–$2.93, opened at $2.90.
- Volume was 103.40K shares, 1.5x its 50-day average of 68.37K.
- Price is -26.1% vs its 50-day average ($3.60) and -55.9% vs its 200-day average ($6.03).
- 52-week range $2.51–$11.88; today's close sits at 2% of that range, 77.6% below the 52-week high.
Oct 5, 2026 — KLRS jumps 4.8% to $2.83
- Closed at $2.83, +4.81% vs the prior close of $2.70. Day range $2.58–$2.89, opened at $2.72.
- Volume was 27.40K shares, 0.4x its 50-day average of 70.98K — lighter than usual.
- Price is -21.8% vs its 50-day average ($3.62) and -53.4% vs its 200-day average ($6.07).
- 52-week range $2.51–$11.88; today's close sits at 3% of that range, 76.2% below the 52-week high.
Oct 2, 2026 — KLRS slides 5.3% to $2.70, a 52-week low on 3.4x normal volume
- Closed at $2.70, -5.26% vs the prior close of $2.85. Day range $2.51–$2.90, opened at $2.90.
- Volume was 235.90K shares, 3.4x its 50-day average of 69.00K — unusually heavy trading.
- Price is -25.8% vs its 50-day average ($3.64) and -55.7% vs its 200-day average ($6.10).
- 52-week range $2.51–$11.88; today's close sits at 2% of that range, 77.3% below the 52-week high.
- That makes 3 straight losses.
KLRS latest news & SEC filings
Every SEC filing by or about KLRS in the last 120 days, explained in plain English. Updated daily, with a same-day refresh for new filings.
Aug 28, 2026 · Form 4 — Insider trade
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
Insider holdings update with no common-stock transactions in the table (often options or derivative awards only).
Aug 11, 2026 · Form 10-Q — Quarterly report
Quarterly report (unaudited financial statements for the quarter)
Quarter ended Jun 30, 2026:
- Net income: -$11.52M (prior year -$11.35M) (loss widened vs Jun 30, 2025)
- Diluted EPS: -$0.48 (prior year -$0.61) (loss narrowed vs Jun 30, 2025)
Aug 11, 2026 · Form 8-K — Major event / current report
Current report — a filing companies must make within 4 business days of a major event
- Item 2.02 — Reported results of operations (earnings release).
This is a results-day filing: the earnings press release is attached as an exhibit.
Aug 3, 2026 · Form 4 — Insider trade
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
Insider holdings update with no common-stock transactions in the table (often options or derivative awards only).
Aug 3, 2026 · Form 3 — New insider holdings
Initial insider ownership statement (Form 3) — a new director, officer or 10% owner disclosed their holdings
Jul 27, 2026 · Form 3 — New insider holdings
Initial insider ownership statement (Form 3) — a new director, officer or 10% owner disclosed their holdings
Jul 20, 2026 · Form 4 — Insider trade
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
Insider holdings update with no common-stock transactions in the table (often options or derivative awards only).
Jul 20, 2026 · Form 3 — New insider holdings
Initial insider ownership statement (Form 3) — a new director, officer or 10% owner disclosed their holdings
Jul 20, 2026 · Form 8-K — Major event / current report
Current report — a filing companies must make within 4 business days of a major event
- Item 5.02 — Change in directors or officers (appointment, departure or pay).
Jul 17, 2026 · Form 8-K — Major event / current report
Current report — a filing companies must make within 4 business days of a major event
- Item 7.01 — Released information under Regulation FD (e.g. a presentation or press release).
- Item 8.01 — Reported other events the company considers important.
Jul 6, 2026 · Form 8-K — Major event / current report
Current report — a filing companies must make within 4 business days of a major event
- Item 5.02 — Change in directors or officers (appointment, departure or pay).
Things to know before you trade KLRS
- Last results release: Aug 11, 2026 (8-K Item 2.02). Previous ones: May 12, 2026, Mar 17, 2026, Nov 12, 2025. Based on that rhythm, the next report is likely around Nov 10, 2026 — an estimate, not a confirmed date.
- How much it moves: over the last 20 sessions the average daily move was 3.00% (largest 6.0%).
- Liquidity: about 84.67K shares (≈$185.43K) trade per day on average. Thin volume can mean wider bid/ask spreads.
- 52-week position: $2.19 vs a range of $2.10–$11.88 (1% of the range).
- Dividends: no cash dividends in the last 2 years.
- Splits: 1:23 on Jan 16, 2025
- Insider trades (Form 4, last 12 months, recent 25 shown): 10 open-market buys, 1 sales; latest: Biocapital, L.P. Samsara bought 244,300 shares on May 20, 2026.
- Latest filings: 10-Q Aug 11, 2026; 8-K Aug 11, 2026; 8-K Jul 20, 2026.
- Share count: 23.80M shares outstanding (Aug 4, 2026), +27.3% vs a year earlier — notable dilution.
- Listing: Nasdaq · industry: Biological Products, (No Diagnostic Substances).
KLRS market data (last 20 sessions)
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Oct 15, 2026 | 2.20 | 2.22 | 2.10 | 2.19 | 57.00K |
| Oct 14, 2026 | 2.22 | 2.23 | 2.11 | 2.13 | 21.00K |
| Oct 13, 2026 | 2.27 | 2.30 | 2.20 | 2.23 | 73.30K |
| Oct 12, 2026 | 2.37 | 2.37 | 2.22 | 2.26 | 122.10K |
| Oct 9, 2026 | 2.46 | 2.55 | 2.36 | 2.36 | 104.40K |
| Oct 8, 2026 | 2.60 | 2.60 | 2.35 | 2.50 | 110.00K |
| Oct 7, 2026 | 2.59 | 2.69 | 2.53 | 2.56 | 74.10K |
| Oct 6, 2026 | 2.90 | 2.93 | 2.61 | 2.66 | 103.40K |
| Oct 5, 2026 | 2.72 | 2.89 | 2.58 | 2.83 | 27.40K |
| Oct 2, 2026 | 2.90 | 2.90 | 2.51 | 2.70 | 235.90K |
| Oct 1, 2026 | 2.88 | 2.89 | 2.76 | 2.85 | 58.60K |
| Sep 30, 2026 | 2.87 | 2.97 | 2.75 | 2.89 | 102.60K |
| Sep 29, 2026 | 2.84 | 2.91 | 2.84 | 2.90 | 51.80K |
| Sep 28, 2026 | 2.91 | 2.97 | 2.81 | 2.85 | 92.80K |
| Sep 25, 2026 | 3.02 | 3.09 | 2.91 | 2.92 | 49.30K |
| Sep 24, 2026 | 3.13 | 3.16 | 3.02 | 3.07 | 33.60K |
| Sep 23, 2026 | 3.20 | 3.21 | 3.12 | 3.12 | 24.00K |
| Sep 22, 2026 | 3.22 | 3.29 | 3.16 | 3.24 | 29.10K |
| Sep 21, 2026 | 3.20 | 3.30 | 3.09 | 3.24 | 88.60K |
| Sep 18, 2026 | 3.18 | 3.23 | 3.04 | 3.20 | 234.40K |
About Kalaris Therapeutics
Kalaris Therapeutics (KLRS) is listed on the Nasdaq and classified by the SEC under “Biological Products, (No Diagnostic Substances)”. Its business address is in BERKELEY HEIGHTS, NJ. State of incorporation: DE. Fiscal year ends December 31. SEC CIK 1754068.
KLRS board of directors & executives
From SEC Form 3/4/5 insider filings made in the last 12 months (date = latest filing).
Directors
| Name | Role | Latest filing |
|---|---|---|
| Anthony P Adamis | Director | Jun 4, 2026 |
| Srinivas Akkaraju | Director | Jun 4, 2026 |
| Michael Dybbs | Director | Jun 4, 2026 |
| Napoleone Ferrara | Director | Jun 4, 2026 |
| David Hallal | Director | Jun 4, 2026 |
| Morana Jovan-Embiricos | Director | Jun 4, 2026 |
| Laurie Keating | Director | Aug 3, 2026 |
| Andrew Oxtoby | See Remarks | Mar 20, 2026 |
| Leone D Patterson | Director | Jun 4, 2026 |
Executive officers
| Name | Title | Latest filing |
|---|---|---|
| Liisa Ann Bayko | Chief Financial Officer | Jul 20, 2026 |
| Matthew Feinsod | Chief Medical Officer | Mar 20, 2026 |
| Matthew Gall | Chief Financial Officer | Mar 20, 2026 |
| Brett R Hagen | Chief Accounting Officer | Mar 23, 2026 |
| Andrew Oxtoby | See Remarks | Mar 20, 2026 |
| Amy O'Leary Vandekop | VP, Corporate Controller | Aug 28, 2026 |
Recent insider buys & sales
| Date | Insider | Type | Shares | Price |
|---|---|---|---|---|
| May 20, 2026 | Biocapital, L.P. Samsara | Buy | 244,300 | $4.83 |
| May 20, 2026 | Opportunity Fund, L.P. Samsara | Buy | 244,300 | $4.83 |
| May 20, 2026 | Opportunity Fund Gp, Llc Samsara | Buy | 244,300 | $4.83 |
| May 20, 2026 | Biocapital Gp, Llc Samsara | Buy | 244,300 | $4.83 |
| May 20, 2026 | Srinivas Akkaraju | Buy | 244,300 | $4.83 |
| Mar 20, 2026 | Brett R Hagen | Sale | 1,915 | $6.72 |
| Dec 18, 2025 | Opportunity Fund, L.P. Samsara | Buy | 479,847 | $10.42 |
| Dec 18, 2025 | Biocapital Gp, Llc Samsara | Buy | 479,847 | $10.42 |
| Dec 18, 2025 | Biocapital, L.P. Samsara | Buy | 479,847 | $10.42 |
| Dec 18, 2025 | Srinivas Akkaraju | Buy | 479,847 | $10.42 |
| Dec 18, 2025 | Opportunity Fund Gp, Llc Samsara | Buy | 479,847 | $10.42 |
KLRS financials (annual, from XBRL filings)
| Fiscal year end | Revenue | Net income | Diluted EPS | Operating cash flow |
|---|---|---|---|---|
| Dec 31, 2025 | — | $-43.44M | -2.85 | $-38.37M |
| Dec 31, 2024 | — | $-69.17M | -51.77 | $-20.67M |
| Dec 31, 2023 | — | $-190.42M | -42.09 | $-124.45M |
| Dec 31, 2022 | — | $-168.71M | -2.20 | $-142.05M |
| Dec 31, 2021 | — | $-171.96M | -2.74 | $-106.32M |
Latest balance sheet: total assets $99.54M, total liabilities $41.87M, cash $43.17M (as of Jun 30, 2026).
KLRS earnings / results-day log
| Date | Filing | Close that day |
|---|---|---|
| Aug 11, 2026 | 8-K Item 2.02 (results) | $3.97 |
| May 12, 2026 | 8-K Item 2.02 (results) | $4.79 |
| Mar 17, 2026 | 8-K Item 2.02 (results) | $8.52 |
| Nov 12, 2025 | 8-K Item 2.02 (results) | $4.96 |
| Aug 13, 2025 | 8-K Item 2.02 (results) | $2.28 |
| May 14, 2025 | 8-K Item 2.02 (results) | $3.38 |
| Mar 18, 2025 | 8-K Item 2.02 (results) | $9.81 |
| Nov 2, 2023 | 8-K Item 2.02 (results) | — |
| Aug 3, 2023 | 8-K Item 2.02 (results) | — |
| May 4, 2023 | 8-K Item 2.02 (results) | — |
| Feb 15, 2023 | 8-K Item 2.02 (results) | — |
| Jan 9, 2023 | 8-K Item 2.02 (results) | — |
Related stocks · Biological Products, (No Diagnostic Substances)
Moderna (MRNA)Amgen (AMGN)Gilead Sciences (GILD)Twist Bioscience (TWST)Argenx Se (ARGX)Biogen (BIIB)Halozyme Therapeutics (HALO)Revolution Medicines (RVMD)Recursion Pharmaceuticals (RXRX)ImmunityBio (IBRX)
Popular today
Micron Technology (MU)Spdr S&P 500 Etf (SPY)Nvidia (NVDA)Sandisk (SNDK)AMD (AMD)Space Exploration Technologies (SPCX)Intel (INTC)Apple (AAPL)Microsoft (MSFT)Meta Platforms (META)Broadcom (AVGO)Tesla (TSLA)
More on KLRS
Information only, not investment advice. BuyMeWhiskey is not a registered investment adviser or broker-dealer; nothing here is a recommendation to buy, sell or hold any security, and there are no price targets. Data comes from SEC EDGAR filings and public end-of-day market data and may be delayed or contain errors. Verify with the company's filings before making decisions. Prices: end-of-day data as of Oct 15, 2026, 4:00 PM ET. Filings: SEC EDGAR. Updated after every US trading day.